Overview:

Monomethyl auristatin E (MMAE), an anti-mitotic medication, is delivered to cancer cells through Polatuzumab vedotin, an antibody-drug combination that targets CD79b. MMAE, a protease-cleavable linker termed maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB), and a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (Polatuzumab) make up the medication. Accelerated FDA clearance for Polatuzumab vedotin was given on June 10, 2019, and Health Canada approval was given on July 9, 2020.

A medication used in conjunction with Rituximab and Bendamustine hydrochloride to treat individuals with diffuse large B-cell lymphoma that returned or did not improve after receiving at least two prior anti-cancer therapy. It is also being investigated for the treatment of further cancers. A monoclonal antibody identified in Polatuzumab vedotin interacts with the protein CD79B, present in certain lymphoma and B cells (white blood cells). It also includes an anti-cancer medication that might aid in the destruction of cancer cells. A specific kind of antibody-drug conjugate is Polatuzumab vedotin.

For Patients:

What Is The Usage of Polatuzumab Vedotin?

Adults with diffuse large B-cell lymphoma who have progressed after at least two previous therapies can get Polatuzumab vedotin, a prescription drug, in combination with Bendamustine and a Rituximab product. Based on a particular response rate, Polatuzumab vedotin has received conditional approval. Studies to determine the drug's effectiveness are still being conducted.

Potentially harmful side effects of Polatuzumab vedotin therapy are crucial since everyone responds to the treatment differently. Polatuzumab vedotin side effects have been reported in some patients and can range from serious to death. If any severe adverse effects manifest, the doctor may stop or change the course of therapy. If one sees any indications of these side effects, be careful to inform the healthcare provider.

Nerve Issues in the Arms and Legs: They might develop as soon as after the first dosage and could get worse with each subsequent dose. The doctor will look out for symptoms, including altered touch sensitivity, tingling or numbness in the hands or feet, nerve pain, burning sensations, any weakening in the muscles, or modifications to the gait.
Reactions to Infusions: Within 24 hours of the infusion, a person might get a fever, chills, rash, breathing issues, low blood pressure, or hives.
Infections: Contact the medical team if a person has chills, a cough, a temperature of at least 100.4°F (38°C), or pain while urinating. Before administering Polatuzumab vedotin, the doctor may also prescribe medication that may help to avoid some infections. Throughout the Polatuzumab vedotin treatment, the doctor will also monitor the blood counts. Taking Polatuzumab vedotin might result in very low blood cell counts.
Uncommon but Harmful Brain Infections: The doctor will look for any indications that a person may have one of these illnesses. If a person feels disoriented, experiences vertigo or loss of balance, has difficulty speaking or walking, or experiences changes in eyesight, call the doctor right away.
Malignant Lysis Syndrome: A result of the quickly deteriorating cancer cells. Nausea, vomiting, diarrhea, and low energy are symptoms.
Possible Liver Damage: Other symptoms include fatigue, weight loss, abdominal discomfort, dark urine, and yellowing of the skin or the whites of the eyes. People with a history of liver disease or who are taking other medications may be more vulnerable.

How Does Polatuzumab Vedotin Work?

A chemotherapeutic medication is coupled to a particular type of monoclonal antibody called Polatuzumab. Copies of a single antibody are known as monoclonal antibodies (MABs). They are created in a laboratory. By concentrating on certain proteins on the cell surface, monoclonal antibodies hunt for cancer cells. Polatuzumab seeks to bind to the B cell surface protein CD79b. Once the chemotherapeutic agent enters the cell, Polatuzumab binds to the CD79b protein, killing the cell.

How Frequently Does One Receive Pola-Br (Polatuzumab Vedotin, Bendamustine, and Rituximab)?

One has Polatuzumab vedotin, Bendamustine, and Rituximab as cycles of therapy. This implies that one takes the medications, followed by a break to let the body heal.

Each therapy cycle lasts 21 days (three weeks). One might experience up to six cycles.
Several hospitals administer cycle one in different ways. Thus, ask the staff that is taking care.
One might structure the treatment cycles as follows:

Cycle 1

Day 1: Rituximab was administered intravenously as a drip (intravenously).
Day 2: Polatuzumab vedotin infused subcutaneously into the blood.

Bendamustine is injected subcutaneously into the blood.

Day 3: Bendamustine injected subcutaneously into the blood.
Day 4 to 21: One receives no care. After that, the treatment cycle is restarted.

Cycles 2 to 6

Day 1: Rituximab was administered intravenously.

A drip of Polatuzumab vedotin into one blood.
Bendamustine is injected subcutaneously into one blood.

Day 2: A trickle of Bendamustine enters the blood.
Day 3 to 21: One receives no care. Rituximab or Polatuzumab can cause allergic reactions in certain persons. This may result in symptoms like the flu, such as fever and vomiting. The initial dose is often taken gradually over a few hours to avoid an allergic response. Before the procedure, a person can also get steroids, antihistamine medication, and Paracetamol. One might have to remain in the hospital while receiving therapy. Consult the group that is taking care of oneself.

Tests: Blood tests are performed both before and during therapy. They measure the number of blood cells and other elements in the blood. Also, they assess how well the kidneys and liver are functioning.

What Are The Adverse Effects Of Polatuzumab Vedotin?

Each person will experience side effects differently in terms of frequency and severity. Also, they depend on the other therapies one is receiving. The most frequent side effects:

Low levels of blood cells (platelets, red blood cells, white blood cells).
Arms and legs have nerve issues.
Fatigue or a lack of energy.
Diarrhea.
Nausea.
Fever.
Diminished appetite.
Infections.

What Are The Caution or Side Effects Of Polatuzumab Vedotin?

Some people might not enjoy Polatuzumab vedotin. Consult the physician if one is pregnant or suspecting pregnancy: Statistics indicate that Polatuzumab vedotin may be harmful to the unborn child. Women should avoid pregnancy.

Pregnant women should refrain from getting pregnant while taking Polatuzumab vedotin. Throughout therapy and for at least three months following their final Polatuzumab vedotin treatment, women should utilize reliable contraception. Throughout therapy and for at least five months following their last Polatuzumab vedotin treatment, men taking Polatuzumab vedotin should utilize an effective method of contraception.
Women should refrain from breastfeeding for at least two months after their last dosage of Polatuzumab vedotin and while they are taking it.
These could not be the only negative consequences. For additional information about the advantages and hazards of Polatuzumab vedotin therapy, speak with the healthcare physician.

When Should One Reach Out to the Medical Team in Case of Side Effects?

The doctor, nurse, or pharmacist will discuss the potential adverse effects. They will monitor the patient while receiving treatment, ask about the health issues, and provide a better solution. As soon as one can, get in touch with the advice line if:

The negative consequences are substantial.
The side effects are not improving.
One is experiencing harsher adverse effects.
Better side effect management might result from early therapy.

For Doctors:

Indication

Adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, are treated in the US with Polatuzumab vedotin, Bendamustine, and Rituximab after receiving at least two previous therapy. Patients who have had at least one previous treatment and are ineligible for an autologous stem cell transplant can use this indication in Canada.

In Canada, Polatuzumab vedotin is also used to treat adult patients with large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), high-grade B-cell lymphoma, Epstein-Barr virus-positive (EBV+) DLBCL NOS, and T-cell/histiocyte rich LBCL, who have not received treatment previously.

Diffuse large B-cell lymphoma, not otherwise specified.
Epstein-barr virus-positive diffuse large B-cell lymphoma.
High-grade B cell lymphoma (HGBCL).
Refractory diffuse large B-cell lymphoma NOS.
Relapsed diffuse large B-cell lymphoma NOS.
Large B cell lymphoma.
T-cell/histiocyte-rich large B-cell lymphoma.

Pharmacodynamics

Malignant B cells are killed by the anti-cancer drug Polatuzumab vedotin, which acts by inducing apoptosis. Most diffuse large B-cell lymphoma (DLBCL) cell lines experienced lethal effects in vitro; this effect persisted across cell lines, regardless of the cell-of-origin subtypes or whether they included mutations in the CD79B gene. In mature CD79b+ B-cell NHL cell lines grown in mice xenograft models, Polatuzumab vedotin induced apoptosis and decreased proliferation. Neutropenia and thrombocytopenia are two immunosuppressive side effects of Polatuzumab vedotin.

Mechanism Of Action:

The antibody-drug combination Polatuzumab vedotin consists of a CD79b-directed antibody, the microtubule-disrupting compound monomethyl auristatin E (MMAE), and a cleavable linker that keeps the components together.

A heterodimer of CD79a and CD79b is known as CD79. When combined with the B cell receptor (BCR), CD79 is responsible for signal transduction and is almost exclusively expressed in B cells, including malignant B cells. CD79b is crucial for BCR expression, transport, and processes, including B cell proliferation and differentiation, and has drawn growing interest as a viable therapeutic target.

Polatuzumab vedotin is internalized when the antibody component attaches to CD79b, and lysosomal proteases break the linker to release MMAE into the cell. A microtubule-disrupting anti-mitotic drug called MMAE causes malignant B cells to become cytotoxic. It attaches to microtubules, prevents the division of B cells by interfering with tubulin and tubulin polymerization, and inhibits mitosis.

Absorption

Following the first Polatuzumab vedotin dosage of 1.8 mg/kg, the mean Cmax (maximum plasma concentration attained by the drug) of antibody-conjugated MMAE and unconjugated MMAE was 803 ( 233) ng/mL and 6.82 ( 4.73) ng/mL (nanogram per milliliter), respectively.

The mean AUCinf (area under the concentration-time curve) of antibody-conjugated MMAE was 1860 ( 966) days x ng/mL, and the mean AUCinf of unconjugated MMAE was 52.3 ( 18.0) days x ng/mL, respectively.

The Volume of Distribution:

Based on population PK studies, the predicted central volume of distribution for Polatuzumab vedotin is 3.15 L.

Protein Binding:

Plasma proteins are 71 percent to 77 percent bound to MMAE. In vitro, the blood-to-plasma ratio ranges from 0.79 to 0.98.

Metabolism

It is anticipated that Polatuzumab vedotin will be catabolized into amino acids, short peptides, unconjugated MMAE (Monomethyl auristatin E), and unconjugated MMAE-related catabolites. CYP3A4 / 5.6 metabolizes MMAE.

Route of Elimination

Polatuzumab vedotin is primarily eliminated in feces, while it is also somewhat secreted in urine.

Half-Life

At Cycle 6, Polatuzumab vedotin had a terminal half-life of approximately 12 days (95 percent CI: 8.1 to 19.5 days). After the initial dosage of Polatuzumab vedotin, unconjugated MMAE has a terminal half-life of around four days.

Clearance

Polatuzumab vedotin is expected to clear the body at a rate of 0.9 L/day.

Drug Interaction:

A substrate for CYP3A4 is MMAE (Monomethyl auristatin E).
Strong inhibitors of CYP3A.
Unconjugated MMAE AUC may rise when a potent CYP3A4 inhibitor is used concurrently, which might worsen the toxicity of Polatuzumab vedotin.
Keep an eye out for poisoning indications.
Strong inducers of CYP3A.
Strong CYP3A4 inducers may reduce unconjugated MMAE AUC when used concurrently.

Abametapir: When coupled with Abametapir, Polatuzumab vedotin's serum levels may rise.
Abciximab: Combining Abciximab with Polatuzumab vedotin may enhance the likelihood or severity of side effects.
Adalimumab: Combining Adalimumab with Polatuzumab vedotin may enhance the likelihood or severity of side effects.
Aducanumab: When Polatuzumab vedotin and Aducanumab are used together, the risk or intensity of side effects may rise.
Alemtuzumab: Combining Alemtuzumab with Polatuzumab vedotin may increase the risk or severity of side effects.
Alirocumab: Combining Alirocumab with Polatuzumab vedotin may increase the likelihood or severity of side effects.
Amiodarone: Using Amiodarone with Polatuzumab vedotin may enhance the likelihood or severity of side effects.
Amivantamab: When Polatuzumab vedotin and Amivantamab are used together, there is a chance that the risk or intensity of side effects will rise.
Amprenavir: When used with Polatuzumab vedotin, the risk or intensity of side effects may increase.
Anifrolumab: Using Anifrolumab with Polatuzumab vedotin may increase the likelihood or severity of side effects.

Food Interactions:

Be cautious when using grapefruit-related items. Monomethyl auristatin E (MMAE), the drug's active component, is a CYP3A4 substrate, and grapefruit consumption may raise plasma levels of MMAE.

Adverse Reactions

Unless otherwise stated, all severity levels are mentioned.

Less than 10 percent drop in lymphocyte count.
Creatinine level rise.
Blood hemoglobin dropped (78 percent).
Lower platelet count (76 percent).
(49 percent) neutropenia.
(49 percent) thrombocytopenia.
Diabetic (47 percent).
Neuropathy in the periphery (40 percent).
Vomiting (38 percent).
SGPT/ALT went up (38 percent).
SGOT/AST went up (36 percent).
Lipase level rise (36 percent).
Insomnia.
Reduction in appetite (27 percent).
Grade 3 anemia (24 percent).
A rise in amylase (24 percent).
Potassium dropped (24 percent less).
Bronchitis (22 percent).
Dyspnea (19 percent).
Nausea (18 percent)
Reactions connected to infusions (18 percent)
Grade 3 hemoglobin dropped by 18 percent.
Grade 3 pneumonia (16 percent).
Hypokalemia (16percent).
Loss of weight.
Lymphopenia.
Infection in the upper respiratory tract (13 percent).
Hypoalbuminemia (13 percent).
Unsteadiness (13 percent).
Lower respiratory infection (10 percent).
Herpes virus infection (12 percent).
Hypocalcemia (11 percent).
1-10 percent Grade 3 Hypokalemia (9 percent).
Reduced calcium, grade 3 (9 percent).
(9 percent) Hypophosphatemia.
Grade 3 potassium declined by 7 percent.
Pancytopenia (7 percent).
Increase in transaminase.
Increase in lipase.
Arthralgia.
Diarrhea.
Pneumonitis (1.7 to 4.4 percent).
Infusion-related response.
Pyrexia (2.2 percent).
Decreased appetite.
Weight loss (2.2 percent).
Blurred vision (1.2 percent).

Contraindications:

None.

Warnings:

Reactions to infusions have been recorded; delayed responses may develop up to 24 hours after receiving Polatuzumab.
Myelosuppression that is severe (such as anemia, thrombocytopenia, or neutropenia) during therapy should be monitored.
Opportunistic infections such as sepsis, pneumonia (including Pneumocystis jiroveci and other fungal pneumonia), herpes virus infection, and cytomegalovirus infection have all been documented as fatal or severe illnesses; continuously watch for infection signs and symptoms.
Hold Polatuzumab and any concurrent chemotherapy if progressive multifocal leukoencephalopathy (PML) is suspected; observe for new or worsening neurological, cognitive, or behavioral problems; and permanently stop treatment if a diagnosis of PML is made.
Tumor lysis syndrome risk may be higher in patients with significant tumor burden and quickly proliferating tumors; constantly monitor these patients and take the necessary precautions, such as prevention for tumor lysis syndrome.
There have been severe cases of hepatotoxicity that were indicative of hepatocellular damage, including increases in transaminases and bilirubin. Hepatotoxicity risk may be raised by pre-existing liver illness, increased baseline liver enzymes, and concurrent medicines; track the amount of bilirubin and liver enzymes.
According to the mechanism of action and results from animal research, fetal damage may happen when a pregnant woman takes a medication.

Radicular Neuropathy

Peripheral neuropathy, including severe instances, can develop as early as the first cycle of therapy. It can also aggravate peripheral neuropathy that already exists. Look for signs of peripheral neuropathy (for example, hypoesthesia, hyperesthesia, paresthesia, dysesthesia, neuropathic pain, burning sensation, weakness, and gait disturbance).

Reproduction-Related Concerns:

Pregnancy

Fetal damage may happen based on results from research done on animals and their mode of action.
No information about the danger of drugs during pregnancy is currently available.
Before starting therapy, check the status of pregnancy in fertile women.
Inform expectant mothers of potential prenatal hazards.

Evidence Relating To Animal Studies:

In animal reproduction research, the small molecule of Polatuzumab vedotin, MMAE, was given to pregnant rats during organogenesis at exposures below the clinical exposure at the suggested dose of 1.8 mg/kg every 21 days. This led to embryo-fetal death and structural abnormalities.

Contraception

Women With the Capability to Procreate: Employ effective contraception while receiving therapy and for three months following the last dosage.
Men with Sexually Active Female Partners: Use effective contraception during therapy and for at least five months following the final dosage in light of results about genotoxicity.

Infertility

Male fertility may be affected based on results from animal research; reversibility is uncertain.

Lactation

There is no information on Polatuzumab vedotin's presence in human milk, its consequences for nursing infants, or milk production. Women should not breastfeed during therapy and for at least two months following the final dosage due to the possibility of major adverse effects in breastfed infants.

For Pregnancy Categories:

A: Usually acceptable. No fetal danger has been identified in controlled investigations of pregnant women.
B: Perhaps agreeable. Animal studies either revealed minimal dangers, and human studies were done and showed no risk, or animal studies showed no risk, but human studies were not available.
C: If advantages exceed hazards, proceed with care. Animal research demonstrates risk, but human studies are either unavailable or have not been conducted.
D: When no safer medication is available, use it in life-threatening situations—positive proof of prenatal danger in humans.
X: Avoid using if pregnant. The risks exceed any possible advantages. There are safer choices.

Dosage Forms & Strengths

Lyophilized Powder for Reconstitution for Injection:

140mg/vial (single-dose vial) (single-dose vial).

Diffuse Large B-Cell Lymphoma:

Indicated for use with Bendamustine and a Rituximab product in treating people with diffuse large B-cell lymphoma (DLBCL) who have experienced recurrence or refractory disease after at least two previous regimens.

Administer for six cycles every 21 days.

Dosage Modifications:

Peripheral Neuropathy

Grades 2-3:

Hold dosage until grade 1 improvement.
If grade 1 recovery occurs on or before day 14, the dosage is permanently reduced to 1.4 mg/kg, and the next cycle is started.
Stop the medication if the dosage was previously lowered to 1.4 mg/kg or the patient has not improved to grade 1 or before day 14.

Grade 4: Stop using the medication.

Reactions Associated With Infusion

Grade 1-3:

Stop the infusion and give comfort care.
Restart infusion at 50 percent of the rate attained before the break; if no infusion-related response happens, the rate may be increased in increments of 50 mg/hr every 30 minutes.
Infuse the dosage over 90 minutes during the following cycle; if no infusion-related response happens, future infusions may be given over 30 minutes.
Prescriptions should be given for all cycles.
If a person gets the first grade 3 symptoms (such as generalized urticaria, wheezing, or bronchospasm), repeated grade 2 urticaria, or grade 3 symptoms, a person should stop taking the medication permanently.

Grade 4

Stop the infusion right away, give supportive care, and stop it permanently.

Grade 3-4 Neutropenia

The intensity of Grades 3 to 4 on day 1 of any cycle: Stop all treatments until the ANC (absolute neutrophil count) is >1000/mcL (microliter).
If lymphoma is the major reason, a decrease or delay in the dosage may not be necessary.
If ANC returns to >1000/mcL by day 7 or earlier
Resuming all therapy with no further dosage lowering
If granulocyte colony-stimulating factor (GCSF) prophylaxis has not already been administered, consider doing so for consecutive cycles.
Following day 7, ANC returns to >1000/mcL
Resume all treatments, and if GCSF prophylaxis has not already been given, consider using it in future cycles.
Think about lowering the Bendamustine dosage if prophylaxis was used.
If the Bendamustine dose reduction has already occurred, 1.4 mg/kg of Polatuzumab vedotin may be an option.

Grades 3 to 4 Thrombocytopenia

The intensity of grades three to four on day one of any cycle: Hold off on any further treatments until platelets become >75,000/mcL.
If lymphoma is the major reason, a decrease or delay in the dosage may not be necessary.
If platelets increase to >75,000/mcL by day seven or earlier.
Resuming all therapy with no further dosage lowering.
After day seven, platelets increase to more than 75,000/mcL.
Resume all treatments while lowering the Bendamustine dosage.
If the Bendamustine dose reduction has already occurred, 1.4 mg/kg of Polatuzumab vedotin may be an option.

Polatuzumab Vedotin: Usage, Pharmacology, Contraindications, and Interactions